A breakthrough in the treatment of psoriasis was the discovery of IL-17 and IL-23 pathways involved in the pathogenesis of psoriasis and the introduction in 2004 of biological drugs containing recombinant proteins (monoclonal antibodies and fusion proteins), which inhibit the activity of inflammatory cytokines [355]. This evidence concerns the gene IL17A and psoriasis.